Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Anistreplase [USAN:INN:BAN]
RN: 81669-57-0
UNII: 5O8V541HJ6

Note

  • An acylated inactive complex of streptokinase and human lysine-plasminogen. After injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis. Its half-life is about 90 minutes compared to 5 minutes for TPA; (TISSUE PLASMINOGEN ACTIVATOR); 16 minutes for UROKINASE-TYPE PLASMINOGEN ACTIVATOR and 23 minutes for STREPTOKINASE. If treatment is initiated within 3 hours of onset of symptoms for acute myocardial infarction, the drug preserves myocardial tissue and left ventricular function and increases coronary artery patency. Bleeding complications are similar to other thrombolytic agents.
 

Classification Codes

  • Cardiovascular Agents
  • Drug / Therapeutic Agent
  • Fibrin Modulating Agents
  • Fibrinolytic
  • Fibrinolytic Agents
  • Hematologic Agents
  • Human Data
* denotes mobile formatted website

Links to Resources

Names and Synonyms

Name of Substance

  • Anistreplase
  • Anistreplase [USAN:INN:BAN]

MeSH Heading

  • Anistreplase

Synonyms

  • Anistreplasa
  • Anistreplasa [INN-Spanish]
  • Anistreplase
  • Anistreplasi
  • Anistreplasum
  • Anistreplasum [INN-Latin]
  • Apsac
  • BRL 26921
  • Eminase
  • UNII-5O8V541HJ6

Systematic Name

  • Anistreplase

Registry Numbers

CAS Registry Number

  • 81669-57-0

FDA UNII

  • 5O8V541HJ6

System Generated Number

  • 0081669570

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
man TDLo intravenous 30units/kg/4M (30units/kg) CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP

CARDIAC: CARDIOMYOPATHY INCLUDING INFARCTION
British Medical Journal. Vol. 306, Pg. 896, 1993.